Literature DB >> 18545891

Patent foramen ovale closure. Pro and cons.

Eustaquio Onorato1, Francesco Casilli, Marco Berti, Gian Paolo Anzola.   

Abstract

Because patent foramen ovale (PFO) represents a lesion which may be repaired a number of expert clinicians believe that mechanical closure should be the primary treatment modality for patients with PFO after cryptogenic stroke; interest has grown on percutaneous devices and in the last years there has been great technological advancement of percutaneous techniques for PFO closure. However, we should not close a PFO before establishing the evidence-based indications. At the same time, efforts to develop safer and more effective closure devices are under way. These devices include those with little or no metal component and those with biodegradable discs. Ideally, we should be able to identify at-risk patients before they sustain a stroke and to prevent stroke by closing the PFO with a device that should result in complete closure, be made of material that conforms to both sides of the septum, and have no risk of erosion, infection, arrhythmia, or thrombogenicity. Randomised trials comparing medical and percutaneous closure approaches are underway, but large patient enrollment is necessary because of the low event rate in the younger patients. Meanwhile, as the complication rate from device implantation decreases and simpler devices are developed with reliability further demonstrated, the threshold for percutaneous closure is likely to decline.

Entities:  

Mesh:

Year:  2008        PMID: 18545891     DOI: 10.1007/s10072-008-0881-x

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  11 in total

Review 1.  Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on patent foramen ovale closure devices.

Authors:  Tina L Pinto Slottow; Daniel H Steinberg; Ron Waksman
Journal:  Circulation       Date:  2007-08-07       Impact factor: 29.690

2.  Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline.

Authors:  Ralph L Sacco; Robert Adams; Greg Albers; Mark J Alberts; Oscar Benavente; Karen Furie; Larry B Goldstein; Philip Gorelick; Jonathan Halperin; Robert Harbaugh; S Claiborne Johnston; Irene Katzan; Margaret Kelly-Hayes; Edgar J Kenton; Michael Marks; Lee H Schwamm; Thomas Tomsick
Journal:  Stroke       Date:  2006-02       Impact factor: 7.914

3.  Interventional atrial septal defect closure using a totally bioresorbable occluder matrix: development and preclinical evaluation of the BioSTAR device.

Authors:  Christian Jux; Harald Bertram; Peter Wohlsein; Michael Bruegmann; Thomas Paul
Journal:  J Am Coll Cardiol       Date:  2006-06-09       Impact factor: 24.094

4.  Minimal access closure of patent foramen ovale: is it also recommended for patients with paradoxical emboli?

Authors:  Ramzi K Deeik; Ryan M Thomas; Pranya Sakiyalak; Sally Botkin; Bradford Blakeman; Mamdouh Bakhos
Journal:  Ann Thorac Surg       Date:  2002-10       Impact factor: 4.330

5.  Patent foramen ovale with paradoxical embolism: mid-term results of transcatheter closure in 256 patients.

Authors:  Eustaquio Onorato; Gloria Melzi; Francesco Casilli; Luigi Pedon; Gianluca Rigatelli; Antonio Carrozza; Pietro Maiolino; Mario Zanchetta; Eva Morandi; Silvia Angeli; Gian Paolo Anzola
Journal:  J Interv Cardiol       Date:  2003-02       Impact factor: 2.279

Review 6.  Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review.

Authors:  Paul Khairy; Clare P O'Donnell; Michael J Landzberg
Journal:  Ann Intern Med       Date:  2003-11-04       Impact factor: 25.391

Review 7.  Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Gregory W Albers; Pierre Amarenco; J Donald Easton; Ralph L Sacco; Philip Teal
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

Review 8.  Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients.

Authors:  Ulrike Krumsdorf; Stefan Ostermayer; Kai Billinger; Thomas Trepels; Elisabeth Zadan; Kathrin Horvath; Horst Sievert
Journal:  J Am Coll Cardiol       Date:  2004-01-21       Impact factor: 24.094

Review 9.  Transcatheter closure of patent foramen ovale after presumed paradoxical embolism.

Authors:  N D Bridges; W Hellenbrand; L Latson; J Filiano; J W Newburger; J E Lock
Journal:  Circulation       Date:  1992-12       Impact factor: 29.690

10.  Patent foramen ovale closure by radiofrequency thermal coaptation: first experience in the porcine model and healing mechanisms over time.

Authors:  Hidehiko Hara; Thomas K Jones; Elena R Ladich; Renu Virmani; David C Auth; Joseph E Eichinger; Robert J Sommer; Robert A Van Tassel; Robert S Schwartz
Journal:  Circulation       Date:  2007-07-30       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.